Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.66 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913724 | 0.93 | BACE1 (0.58) | BACE1BACE2CYP2D6KCNH2 | |
| SCHEMBL989722 | 0.92 | BACE1 (0.65) | BACE1BACE2CYP2D6KCNH2PSEN1 | |
| SCHEMBL991247 | 0.91 | BACE1 (0.59) | BACE1BACE2KCNH2 | |
| SCHEMBL990433 | 0.88 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL989772 | 0.88 | BACE1 (0.63) | BACE1BACE2 | |
| SCHEMBL11913722 | 0.87 | BACE1 (0.57) | BACE1BACE2 | |
| SCHEMBL6919949 | 0.86 | BACE1 (0.67) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL989821 | 0.86 | BACE1 (0.68) | BACE1BACE2 | |
| SCHEMBL11913714 | 0.86 | BACE1 (0.52) | BACE1BACE2 | |
| SCHEMBL990426 | 0.86 | BACE1 (0.63) | BACE1BACE2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | claimed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | claimed |
| EP-2456771-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | claimed |
| WO-2011009897-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | claimed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2456771-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009897-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009897-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885CYP2D6 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.